Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia

Psychological Medicine

Volumn 42, Issue 11, 2012, Pages 2275-2285

  Lahti, M ^a   Tiihonen, J ^b,c,d   Wildgust, H ^e   Beary, M ^f   Hodgson, R ^g   Kajantie, E ^d,h   Osmond, C ⁱ   Raikkonen K ^a   Eriksson, J ^a,d,h,j,k  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e Hiram Consulting   (United Kingdom)

^f Priority Hospital North London   (United Kingdom)

^g Lyme Brook Centre   (United Kingdom)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j FOLKHÄLSAN RESEARCH CENTER   (Finland)

^k VAASA CENTRAL HOSPITAL   (Finland)

more..

Author keywords

Cardiovascular disease; longitudinal studies; morbidity; mortality; pharmacotherapy; psychosis

Indexed keywords

AGED; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY DISEASE; FEMALE; FINLAND; HUMAN; MALE; MORTALITY; REGISTER; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA;

AGED; COMORBIDITY; CORONARY DISEASE; FEMALE; FINLAND; HUMANS; MALE; REGISTRIES; SCHIZOPHRENIA; SEX FACTORS; STROKE;

EID: 84870050297     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291712000396     Document Type: Article

References (49)

1. Barker DJ, Forsén T, Eriksson JG, Osmond C (2002). Growth and living conditions in childhood and hypertension in adult life: a longitudinal study. Journal of Hypertension 20, 1951-1956
2. Basu D, Aggarwal M (2009). Mortality in patients with schizophrenia. Lancet 374, 1591
3. Brown S, Kim M, Mitchell C, Inskip H (2010). Twenty-five year mortality of a community cohort with schizophrenia. British Journal of Psychiatry 196, 116-121
4. Brown S, Mitchell C (2011). Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Social Psychiatry and Psychiatric Epidemiology. Published online 11 May 2011. doi:10.1007/s00127-011- 0392-6
5. Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M, Stewart R (2011). Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 6, e19590. doi:10.1371/journal.pone.0019590
6. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (2008). Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125
7. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Mö ller HJ, Gautam S, Detraux J, Correll CU (2011a). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10, 138-151
8. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Mö ller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S (2011b). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10, 52-77
9. De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J (2006). Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 67, 1889-1896
10. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000). Mental disorders and use of cardiovascular procedures after myocardial infarction. Journal of the American Medical Association 283, 506-511
11. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM (2001). Quality of medical care and excess mortality in older patients with mental disorders. Archives of General Psychiatry 58, 565-572
12. Flegal KM, Graubard BI, Williamson DF, Gail MH (2007). Cause-specific excess deaths associated with underweight, overweight, and obesity. Journal of the American Medical Association 298, 2028-2037
13. Forsén T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D (2000). The fetal and childhood growth of persons who develop type 2 diabetes. Annals of Internal Medicine 133, 176-182
14. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E (1997). Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Annals of Internal Medicine 126, 761-767
15. Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150, 1115-1121
16. Hippisley-Cox J, Parker C, Coupland C, Vinogradova Y (2007). Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart 93, 1256-1262
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008). Cancer statistics (2008). CA: a Cancer Journal for Clinicians 58, 71-96
18. Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, Warren KR, Feldman S, Shim J, Love RC, Dixon L (2011). Cigarette smoking and mortality risk in people with schizophrenia. Schizophrenia Bulletin 37, 832-838
19. Keskimäki I, Aro S (1991). The accuracy of data on diagnoses, procedures and accidents in the Finnish Hospital Discharge Register. International Journal of Health Services 2, 15-21
20. Kieseppä T, Partonen T, Kaprio J, Lönnqvist J (2000). Accuracy of register-and record based bipolar I disorder diagnoses in Finland-a study of twins. Acta Neuropsychiatrica 12, 106-109
21. Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, Blow FC (2009). Excess heartdisease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. General Hospital Psychiatry 31, 555-563
22. Kisely S, Campbell LA, Wang Y (2009). Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. British Journal of Psychiatry 195, 545-550
23. Kisely S, Smith M, Lawrence D, Cox M, Campbell LA, Maaten S (2007). Inequitable access for mentally ill patients to some medically necessary procedures. Canadian Journal of Psychiatry 176, 779-784
24. Lahti RA, Penttilä A (2001). The validity of death certificates: routine validation of death certification and its effects on mortality statistics. Forensic Science International 115, 15-32
25. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB (2009). Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Archives of General Psychiatry 66, 713-720
26. Leppälä JM, Virtamo J, Heinonen OP (1999). Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland. European Journal of Epidemiology 15, 155-160
27. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913
28. Mähönen M, Salomaa V, Brommels M, Molarius A, Miettinen H, Pyörälä K, Tuomilehto J, Arstila M, Kaarsalo E, Ketonen M, Kuulasmaa K, Lehto S, Mustaniemi H, Niemelä M, Palomäki P, Torppa J, Vuorenmaa T (1997). The validity of hospital discharge register data on coronary heart disease in Finland. European Journal of Epidemiology 13, 403-415
29. Mäkikyrö T, Isohanni M, Moring J, Hakko H, Hovatta I, Lönnqvist J (1998). Accuracy of register-based schizophrenia diagnoses in a genetic study. European Psychiatry 13, 57-62
30. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19-32
31. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine 42, 125-147
32. Mitchell AJ, Lawrence D (2011). Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. British Journal of Psychiatry 198, 434-441
33. Mitchell AJ, Lord O (2010). Do deficits in cardiac care influence high mortality rates in schizophrenia ? A systematic review and pooled analysis. Journal of Psychopharmacology 24, 69-80
34. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Canpagna E, Newcomer JW (2010). Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry 67, 17-24
35. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86, 15-22
36. Nomesco (2010). NOMESCO Report on Mortality Statistics for the Nordic/Baltic Countries. Nomesco: Copenhagen
37. Osmond C, Kajantie E, Forsén TJ, Eriksson JG, Barker DJ (2007). Infant growth and stroke in adult life: the Helsinki birth cohort study. Stroke 38, 264-270
38. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, Mähönen M, Niemelä M, Kuulasmaa K, Palomäki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesäniemi YA, Pyörälä K, Salomaa V (2005). The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation 12, 132-137
39. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 64, 19-28
40. Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M (2007). Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatric Services 58, 207-212
41. Pihlajamaa J, Suvisaari J, Henriksson M, Heilä H, Karjalainen E, Koskela J, Cannon M, Lönnqvist J (2008). The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. Nordic Journal of Psychiatry 62, 198-203
42. Plomondon ME, Ho PM, Wang L, Greiner GT, Shore JH, Sakai JT, Fihn SD, Rumsfeld JS (2007). Severe mental illness and mortality of hospitalised ACS patients in the VHA. BMC Health Services Research 7, 146
43. Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, Sattar N (2010). Statins and all-cause mortality in high-risk primary prevention. Archives of Internal Medicine 170, 1024-1031
44. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168, 603-609
45. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009). 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627
46. Tolonen H, Salomaa V, Torppa J, Sivenius J, Immonen-Räihä P, Lehtonen A; for the FINSTROKE register (2007). The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. European Journal of Cardiovascular Prevention and Rehabilitation 14, 380-385
47. Vrecer M, Turk S, Drinovec J, Mrhar A (2003). Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. International Journal of Clinical Pharmacology and Therapeutics 41, 567-577
48. Wildgust HJ, Beary M (2010). Are there modifiable risk factors which will reduce the excess mortality in schizophrenia ? Journal of Psychopharmacology 24, 37-50
49. WHO (2009). Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. WHO Press: Geneva.